What Is a CALR Exon 9 Mutation and What Does It Mean?

A CALR exon 9 mutation is an acquired genetic change in the calreticulin gene, found almost exclusively in blood cancers known as myeloproliferative neoplasms. It was first identified in 2013 and quickly recognized as one of the three major “driver” mutations behind these diseases, alongside the better-known JAK2 and MPL mutations. The mutation rewires a protein that normally manages calcium inside cells, turning it into an engine for uncontrolled blood cell production. Understanding what this mutation is, how it behaves, and what it means for a patient’s outlook requires some unpacking, because the details genuinely matter for treatment decisions and long-term monitoring.

What Calreticulin Normally Does

Calreticulin is a protein that lives inside a compartment of the cell called the endoplasmic reticulum. Its main jobs are managing calcium levels and acting as a quality-control chaperone that helps newly made proteins fold into the right shape. It is one of the most highly conserved proteins across species, meaning evolution has kept it nearly unchanged for a very long time because its functions are so essential.¹ The protein’s tail end, encoded partly by exon 9 of the CALR gene, carries a strong negative electrical charge that helps it bind calcium. This tail is the region the mutation disrupts.

How the Mutation Changes the Protein

All CALR exon 9 mutations involve small insertions or deletions of DNA that shift the reading frame, meaning the cell reads the genetic code out of alignment from that point forward. Researchers have catalogued at least 36 distinct insertion or deletion variants, and every single one shifts the code into the same alternative reading frame, producing a new, abnormal tail on the calreticulin protein.² The normal tail is negatively charged; the mutant tail is positively charged. That flip in electrical character is what drives the disease.

These mutations are somatic, meaning they arise spontaneously in a blood-forming stem cell during a person’s lifetime. They are not inherited from parents and are not passed to children. A study of families with multiple members who had essential thrombocythemia or myelofibrosis confirmed that all CALR mutations tested were found only in blood cells, not in the patients’ non-blood cells like T lymphocytes.³ So if you have a CALR mutation, you acquired it on your own, and your children are not at direct genetic risk for it.

How It Drives Blood Cancer

The positively charged mutant tail gives calreticulin a new and unwanted ability: it physically latches onto a receptor on the surface of blood cell precursors called MPL, the thrombopoietin receptor. Normal calreticulin does not do this. The mutant form does, and by binding MPL it switches the receptor on without thrombopoietin, the hormone that normally activates it.⁴ This triggers a signaling cascade through JAK2, STAT5, and ERK pathways, essentially telling the cell to keep growing and dividing even when no growth signal is present.⁵ Because MPL is heavily expressed on cells that make platelets, the most immediate result is overproduction of platelets. This is why CALR mutations are most commonly found in essential thrombocythemia and myelofibrosis.

Interestingly, the mutant calreticulin also appears on the outer surface of the abnormal cells, which does not happen with the normal protein. That surface exposure has attracted attention as a potential target for new therapies, since the immune system could theoretically be trained to recognize and attack cells displaying this abnormal protein.⁶

Type 1 Versus Type 2 and Why It Matters

Although dozens of CALR exon 9 variants exist, two account for the vast majority. Type 1 is a 52-base-pair deletion, and Type 2 is a 5-base-pair insertion. Together, these two variants make up more than 80% of all CALR mutations found in essential thrombocythemia.⁷ Less common variants are typically grouped as “type 1-like” or “type 2-like” depending on how much of the original tail they delete, since the degree of tail disruption seems to influence behavior.

The distinction is not just academic. In essential thrombocythemia, type 2 mutations tend to appear in younger patients and are associated with higher platelet counts than type 1.⁷ In myelofibrosis, the difference is starker. A study of over 300 myelofibrosis patients with CALR mutations found that those with type 1 or type 1-like mutations survived significantly longer than those with type 2 or type 2-like mutations, who had a median survival of about 16 years. The type 2-like group had roughly double the risk of death after adjusting for other factors.⁸ So when a lab report says “CALR mutation detected,” knowing whether it is type 1 or type 2 adds meaningful prognostic information, especially in myelofibrosis.

Which Diseases Carry CALR Mutations

CALR exon 9 mutations are strongly linked to two myeloproliferative neoplasms: essential thrombocythemia (ET), where the body makes too many platelets, and primary myelofibrosis (PMF), where scar tissue gradually replaces normal bone marrow. In one large study, CALR mutations were found in about 22% of ET patients and 17% of PMF patients overall.⁹ But those percentages climb sharply when you look only at patients who lack JAK2 and MPL mutations. In that JAK2/MPL-negative group, CALR mutations account for 70 to 84% of cases.¹⁰

CALR mutations are conspicuously absent from polycythemia vera, the third major myeloproliferative neoplasm, which is driven almost entirely by JAK2 mutations. They do occasionally turn up in myelodysplastic syndromes and other myeloid cancers, but at much lower rates.¹⁰

Thrombosis Risk Compared to JAK2

One of the most clinically relevant findings about CALR-mutated ET is that it carries a lower risk of blood clots than JAK2-mutated ET. Research comparing the two groups found that the risk of thrombosis in JAK2-mutated ET was roughly double that seen in CALR-mutated ET.¹¹ This difference is large enough to influence treatment decisions. Patients with CALR-mutated ET, especially younger ones without other cardiovascular risk factors, may not need the same intensity of antiplatelet or cytoreductive therapy that JAK2-mutated patients require.

This lower clot risk has led some physicians to describe CALR-mutated ET as a more “benign” condition, but that framing deserves some pushback. A study from the Weill Cornell MPN Center tracked long-term outcomes and found that while CALR-mutated ET patients had virtually no thrombotic events over 20 years, their risk of progressing to myelofibrosis was substantially higher than in JAK2-mutated ET. In a multivariable analysis adjusting for age, sex, and white blood cell count, CALR-mutated ET carried over eleven times the risk of post-ET myelofibrosis compared to JAK2-mutated disease.¹² In other words, CALR-mutated ET trades one risk for another: fewer clots but a greater chance the disease eventually transforms into the more serious condition of myelofibrosis.

How the Mutation Is Detected

If a doctor suspects a myeloproliferative neoplasm and JAK2 testing comes back negative, CALR exon 9 testing is the standard next step. Several laboratory methods can identify these mutations. Sanger sequencing, the traditional gold standard for reading DNA, works but has a relatively high detection threshold, meaning it can miss the mutation if the abnormal cells make up only a small fraction of the sample. Fragment analysis using PCR and capillary electrophoresis is faster and more sensitive, making it a common first-line screening tool.¹³ Next-generation sequencing (NGS) offers the most sensitivity, capable of detecting the mutation when it is present at as low as a 1% allele burden, and it also provides precise sequence-level detail about which variant is present.¹⁴

In practice, many labs use fragment analysis as an initial screen and reflex to NGS when the result is ambiguous or when they need to determine the exact mutation type. Each approach has trade-offs in cost, turnaround time, and sensitivity, but they all reliably catch the common type 1 and type 2 mutations. The challenge increases for the rare, non-canonical variants, where fragment analysis alone may produce results that need NGS confirmation to interpret correctly.¹³

Monitoring the Mutation Over Time

Once a CALR mutation is identified, tracking the proportion of mutant cells in the blood, known as the allele burden, can provide useful clinical information. Researchers developed sensitive quantitative PCR assays to measure the allele burden of type 1 and type 2 mutations and found that the burden closely tracked with platelet and white blood cell counts, hemoglobin levels, and a marker of bone marrow activity called LDH.¹⁵

A rising allele burden is a warning sign. A study that followed CALR-mutated patients over time found that those whose disease progressed showed a significant average increase in allele burden of about 17 percentage points, while those with stable disease showed essentially no change. This association held regardless of what additional mutations the patient carried.¹⁶ Serial allele burden monitoring is not yet standard everywhere, but it is gaining traction as a way to identify patients whose disease may be evolving before clinical symptoms clearly change.

Treatment Considerations

There is no treatment that specifically targets mutant calreticulin approved for clinical use today. Most patients with CALR-mutated ET are managed with observation, aspirin, or cytoreductive therapy such as hydroxyurea or interferon alfa, depending on their risk profile. For myelofibrosis, the JAK inhibitor ruxolitinib is a mainstay, and it works in CALR-mutated patients because the mutant calreticulin still signals through JAK2. However, there are hints that the response may not be identical to JAK2-mutated myelofibrosis. One analysis found that CALR-mutated myelofibrosis patients on ruxolitinib had a significantly lower rate of symptom improvement at six months compared to JAK2-mutated patients (about 56% versus 67%), along with higher rates of anemia.¹⁷ The spleen size responses were similar between groups, so ruxolitinib is still useful, but the symptom gap suggests the mutation background may modulate treatment response in ways that merit attention.

Interferon alfa is particularly interesting in the CALR-mutated setting because it can sometimes reduce the mutant allele burden over time, potentially shrinking the abnormal clone. Researchers have documented varying dynamics of allele burden reduction under interferon treatment, with some patients achieving deep molecular responses.¹⁵ Whether achieving a molecular response translates into longer-term disease modification remains an active area of research.

Antibodies Targeting Mutant Calreticulin

Because the mutant calreticulin protein displays its abnormal tail on the cell surface, it presents a target that the immune system does not see on healthy cells. This has prompted efforts to develop antibodies that specifically recognize the mutant protein. Several research groups are pursuing therapeutic antibodies and antibody-drug conjugates designed to seek out cells displaying mutant calreticulin and either destroy them directly or flag them for immune attack.⁶ These approaches are still in early-stage development, but they represent a genuinely mutation-specific strategy rather than the broad-spectrum approach of current JAK inhibitors. If successful, they could change the treatment landscape for CALR-mutated patients considerably.

When CALR Mutations Show Up Without Disease

With the increasing use of broad genomic testing, CALR mutations occasionally turn up in people who do not have a diagnosable myeloproliferative neoplasm. This situation is called clonal hematopoiesis of indeterminate potential, or CHIP, and it means a small population of blood cells carries the mutation but has not yet caused any clinical abnormality. A published case report followed a healthy individual with CALR-positive CHIP for 12 years before the person eventually developed pre-fibrotic myelofibrosis.¹⁸ A single case report cannot establish how often this progression happens, but it illustrates that a CALR mutation detected incidentally is not something to ignore. It warrants periodic follow-up blood counts and clinical assessment, even if no intervention is needed immediately.

CALR Mutations in Children and Young Adults

Myeloproliferative neoplasms are overwhelmingly diseases of middle-aged and older adults, but they do occur in children and teenagers. In pediatric essential thrombocythemia, the clinical picture differs from adults in several ways. Only about 25 to 40% of pediatric ET cases carry one of the known driver mutations, meaning the majority of children with ET are “triple negative” for JAK2, CALR, and MPL.¹⁹ When CALR mutations are found in young patients, the disease generally follows a milder course than in adults. Thrombotic events are rare, and bleeding complications tend to be minor. The challenge in pediatric cases is that the adult prognostic scoring systems and treatment guidelines may not apply cleanly, and the very long time horizon means even a slowly progressive disease could eventually matter.

Non-Standard Variants and Germline Lookalikes

While type 1 and type 2 make up the lion’s share of CALR exon 9 mutations, a minority of patients harbor rare, non-standard variants. A recent analysis found that non-type 1/type 2 CALR mutations appeared in roughly 0.8% of patients being tested for suspected myeloproliferative neoplasms, and some of these may not actually be linked to disease at all.²⁰ One red flag the study highlighted: when a non-standard CALR variant is detected at an allele frequency near 50%, it may actually be a germline (inherited) variant rather than a somatic mutation. Germline CALR variants are generally not disease-causing in the same way and require a different workup. If your lab report shows an unusual CALR variant at a high allele frequency, your hematologist should consider testing non-blood tissue like a cheek swab to determine whether it is truly somatic or inherited.²⁰